# Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients

> **NCT00900146** · PHASE2,PHASE3 · TERMINATED · sponsor: **Novartis** · enrollment: 556 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Canakinumab
- **DRUG:** Metformin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00900146
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-04
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 556 (ACTUAL)
- **Why stopped:** Numerically modest lowering of HbA1c with canakinumab in combination with metformin was inadequate to continue patients with T2DM into Period IV of this study.
- **Last updated:** 2012-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00900146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00900146, "Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00900146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*